These data were taken to conclude, that revascularization of significantly ischemic myocardium improves survival (1). However, our present rationale would require differentiating the data further into outcomes of patients having undergone CABG or PCI. Although the overall mortality rate for both invasive...
Tokenization 101: Enhance data security and PCI compliance with credit card tokenization. Reduce breaches, costs, and secure card holder dates to increase customer confidence.
PII must be protected, the confidentiality of the end-user needs to be guaranteed, it's never okay to share PII over insecure channels and DNS is, by design, an insecure channel. DNS can only guarantee data integrity (dnssec), not confidentiality. ChatGPT's view aligns with mine Conside...
Background Although there is data on the safety and feasibility of same-day discharge (SDD) after percutaneous coronary intervention (PCI), overnight hospitalization (ON) continues to be prevalent. No systematic reviews that have comprehensively examined this subject currently exist. This study aimed ...
International and local laws may compel businesses to implement additional policies and technical solutions for handling cardholder data and personally identifiable information (PII). Such laws and regulations take precedence over PCI data security standards. ...
pii: S0914-5087(13)00291-8. 亚洲数据 审批号:85.303,022 有效期至2015年2月26日 ALPACS研究主要终点:PCI术后30天内MACE发生率 主要终点:与对照组相比,阿托伐他汀组患者PCI术后30天内的MACE(死亡、心梗、靶血管重建)发生率无显著统计学差异。 亚洲数据 ALPACS表明: 在亚裔人群中阿托伐他汀强化治疗较...
pii: S0914-5087(13)00291-8. 亚洲数据 审批号:85.303,022 有效期至2016年2月26日 ALPACS研究主要终点:PCI术后30天内MACE发生率 主要终点:与对照组相比,阿托伐他汀组患者PCI术后30天内的MACE(死亡、心梗、靶血管重建)发生率无显著统计学差异。 亚洲数据 ALPACS表明: 在亚裔人群中阿托伐他汀强化治疗较...
Participants in the National Cardiovascular Data CathPCI Registry undergoing PCI of a bypass graft to the left anterior descending artery (LAD) from July 2009−December 2011 were included. Patients were divided as follows: LIMA; saphenous vein graft (SVG); or other arterial graft (Other). Clinic...
These data are supplemented by the lack of difference in terms of MVO extent (4.6% [IQR: 2.0% to 6.4%] vs. 2.8% [IQR: 1.6% to 5.4%]; p = 0.26) (Figure 4C) or presence of intramyocardial hemorrhage (75.0% vs. 51.6%; p = 0.10) (Table 3) when patients with MVO and high IMR...
Randomized data on the results of platelet function tests in patients undergoing primary PCI for STEMI treated by clopidogrel or prasugrel are scarce. We have chosen the VASP-PRI as primary outcome because the result is not affected by the concomitant use of GP IIb/IIIa inhibitors and the result...